Singapore markets open in 4 hours 45 minutes

Voyageur Pharmaceuticals Ltd. (VM.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.04500.0000 (0.00%)
At close: 12:20PM EDT
Full screen
Previous close0.0450
Open0.0450
Bid0.0400 x 0
Ask0.0450 x 0
Day's range0.0450 - 0.0450
52-week range0.0450 - 0.1200
Volume49,450
Avg. volume58,585
Market cap3.211M
Beta (5Y monthly)1.30
PE ratio (TTM)N/A
EPS (TTM)-0.0160
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Voyageur Secures Exclusive Rights To One Of The Worlds Rarest Pharmaceutical Minerals, Creating A New Era In Carbon Based Drug Development

    Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (VYYRF) (the “Company” or “Voyageur”) is pleased to announce it has signed an LOI with an established international mining company (the “Counterparty”) that has developed a low cost method to extract the natural occurring carbon molecule, C-60 to C-90, from  large natural-occurring fullerene resources. “Voyageur will be the first company to be able to mass produce C-60 at a low cost, allowing for multiple drug products to be developed,” states Brent Willis, CEO of Voyageur Pharmaceuticals. “The barriers for C-60 based drugs has now been broken, which opens up the industry to develop new effective drugs and health care products on an economic scale,” continues Brent Willis.

  • GlobeNewswire

    Voyageur Restructures its ImagingX Joint Venture

    Voyageur Pharmaceuticals Ltd. (VM.V) (the “Company” or “Voyageur”) is pleased to announce the dissolution of the current joint venture with Chief Medical Supplies (“Chief”). Voyageur and Chief have worked together to create a new working relationship that is more beneficial to both parties. Voyageur will move the projects forward using manufacturing agreements in place of the joint venture structure.

  • GlobeNewswire

    Voyageur Pharmaceuticals Announces its “From The Earth To The Bottle” Iodine Contrast Strategy

    Voyageur Pharmaceuticals Ltd. (TSX.V:VM, USA:VYYRF) (the “Company” or “Voyageur”) is pleased to announce the fully-integrated iodine business strategy which complements its ongoing barium contrast marketing strategy. Iodine contrast is one of highest volume consumables in healthcare. Water soluble, iodinated contrast media contains iodine atoms used for x-ray-based imaging such as computed tomography (CT), fluoroscopy, angiography and venography.